Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
18
IPIX Quote, Financials, Valuation and Earnings
Last price:
$0.0000
Seasonality move
:
18.34%
Day range:
$0.0001 - $0.0009
52-week range:
$0.0000 - $0.0186
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.31x
Volume:
277.7K
Avg. volume:
334.3K
1-year change:
600%
Market cap:
$362.8K
Revenue:
--
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Innovation Pharmaceuticals, Inc. has -- downside to fair value with a price target of -- per share.
IPIX vs. S&P 500
-
Over the past 5 trading days, Innovation Pharmaceuticals, Inc. has underperformed the S&P 500 by -0.1% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Innovation Pharmaceuticals, Inc. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Innovation Pharmaceuticals, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Innovation Pharmaceuticals, Inc. reported revenues of --.
Earnings Growth
-
Innovation Pharmaceuticals, Inc. has grown year-over-year earnings for 8 quarters straight. In the most recent quarter Innovation Pharmaceuticals, Inc. reported earnings per share of --.
Enterprise value:
193.8K
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.09x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2022-09-30 | 2023-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $18K | -- | -- | -- | |
| Gross Profit | -$379K | -$362K | -$375K | -$93K | -$94K | |
| Operating Income | -$9.9M | -$6.1M | -$2.4M | -$1.4M | -$802K | |
| EBITDA | -$9.5M | -$5.7M | -$2M | -$1.3M | -$708K | |
| Diluted EPS | -$0.04 | -$0.01 | -$0.01 | -$0.00 | -$0.00 | |
| Period Ending | 2019-09-30 | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $967K | $7.3M | $11.4M | $3.1M | $940K | |
| Total Assets | $4.3M | $11.7M | $14.7M | $9.3M | $6.7M | |
| Current Liabilities | $7.5M | $6.6M | $6.2M | $5.1M | $5M | |
| Total Liabilities | $8.9M | $7M | $6.4M | $5.9M | $5.5M | |
| Total Equity | -$4.5M | $4.7M | $8.3M | $3.4M | $1.2M | |
| Total Debt | $1.4M | $379K | $206K | $786K | $457K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2022-09-30 | 2023-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$10M | -$5.1M | -$2M | -$791K | -$677K | |
| Cash From Investing | -$86K | -$4.1M | -$58K | -$4K | -$2K | |
| Cash From Financing | $14.1M | $946K | -$54K | -$44K | $25K | |
| Free Cash Flow | -$10.1M | -$5.2M | -$2.1M | -$795K | -$679K | |
IPIX
Sector
Market Cap
$362.8K
$27.9M
Price % of 52-Week High
3.76%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.49%
1-Year Price Total Return
600%
-16.66%
Beta (5-Year)
131.062
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.0007
200-day SMA
Sell
Level
$0.0008
Bollinger Bands (100)
Sell
Level
0.0013 - 0.0013
Chaikin Money Flow
Sell
Level
-460.3K
20-day SMA
Sell
Level
$0.0008
Relative Strength Index (RSI14)
Sell
Level
46.8938
ADX Line
Buy
Level
17.2317
Williams %R
Buy
Level
-84.6154
50-day SMA
Sell
Level
$0.0010
MACD (12, 26)
Buy
Level
0.0001
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Neutral
Level
360.1K
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Innovation Pharmaceuticals, Inc. is a clinical stage biotechnology company, which engages in the development of therapies with anti-infective, oncology, anti-inflammatory, and dermatology applications. It focuses on its antifungal drug candidate called Brilacidin. The company was founded by Krishna Kumar Menon, George W. Evans, and Leo Ehrlich on June 20, 2007 and is headquartered in Wakefield, MA.
Stock Forecast FAQ
In the current month, IPIX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The IPIX average analyst price target in the past 3 months is --.
-
Where Will Innovation Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Innovation Pharmaceuticals, Inc. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Innovation Pharmaceuticals, Inc.?
Analysts are divided on their view about Innovation Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Innovation Pharmaceuticals, Inc. is a Sell and believe this share price will rise from its current level to --.
-
What Is Innovation Pharmaceuticals, Inc.'s Price Target?
The price target for Innovation Pharmaceuticals, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is IPIX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Innovation Pharmaceuticals, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of IPIX?
You can purchase shares of Innovation Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Innovation Pharmaceuticals, Inc. shares.
-
What Is The Innovation Pharmaceuticals, Inc. Share Price Today?
Innovation Pharmaceuticals, Inc. was last trading at $0.0000 per share. This represents the most recent stock quote for Innovation Pharmaceuticals, Inc.. Yesterday, Innovation Pharmaceuticals, Inc. closed at $0.0007 per share.
-
How To Buy Innovation Pharmaceuticals, Inc. Stock Online?
In order to purchase Innovation Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get IPIX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
IPIX
Sector
P/E ratio
--
23.85x
PEG ratio
--
-0.01x
P/B ratio
0.31x
1.81x
Price / LTM sales
--
1.58x
Growth Metrics
IPIX
Sector
Revenue growth
--
4.62%
Earnings growth
--
10.5%
Revenue (5-year growth)
--
6.5%
Earnings forecast
--
-$0.21
Profitability
IPIX
Sector
Profitability FY 2025
--
$3.6M
Return on invested capital
--
-31.87%
Return on assets
--
-28.18%
Return on equity
--
-37.63%
Earnings Date
Last Earnings Date
Nov
8
Next Earnings Date
Dec
21
Estimated Next Earnings Date
Mar
22
Balance Sheet
IPIX
Sector
Total cash
--
$26.4M
Short term investments
--
$25.7M
Total assets
$7.5M
$76.9M
Long term debt
--
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
